Wordt geladen...

RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0

OBJECTIVE: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 has been rapidly accepted in clinical trials as a standard measure to assess tumor response to therapy and is expected to improve response assessment, especially in genomically defined patients. The impact of RECIST 1.1 was compare...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Nishino, Mizuki, Cardarella, Stephanie, Jackman, David M., Ramaiya, Nikhil H., Rabin, Michael S., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731976/
https://ncbi.nlm.nih.gov/pubmed/23789698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2214/AJR.12.9668
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!